» GU Cancer

GU Cancer

Phase II Trial to Evaluate Benefit of Early Switch from first-Line Docetaxel/Prednisone to Cabazitaxel/Prednisone and the opposite sequence, exploring molecular markers and mechanisms of taxane resistance in men with Metastatic Castration-Resistant Prostate Cancer (mCRPC) who have not received prior chemotherapy
The purpose of the study is to explore the benefit of an early switch from Docetaxel/Prednisone to Cabazitaxel/Prednisone in men with certain types of prostate cancer; to assess effectiveness of the two treatment strategies, switch from Cabazitaxel/Prednsone to Docetaxel/Prednisone and Docetaxel/Predinisone to Cabazitaxel/Prednisone; and to evaluate the effectivess in patients receiving initial Taxane (Decetaxel or Cabazitaxel) treatment before the switch and effectivess under the alternate Taxan (Docetaxel or Cabazitaxel) after the switch.
Website: http://clinicaltrials.gov/ct2/show/NCT01718353?term=Phase+II+Trial+to+Evaluate+Benefit+of+Early+Switch+from+first-Line&rank=1¬
Principal Investigator: Jason Taksey, MD.
Research Staff:   Elizabeth Egan, RN (443) 481-5811
                                  Steven P. DeMartino, CCRC, CRT, RPFT, AEC: (443) 481-4390

Adjuvant Axitinib Treatment of Renal Cancer: A Randomized Double-Blind Phase 3 Study of Adjuvant Axitinib vs. Placebo in Subjects at High Risk of Recurrent Renal Cell Cancer¬
The purpose of this trial is to determine if supplementing therapy with Axitinib will prevent or delay the recurrence of renal cell cancer after surgery to remove the primary tumor in high risk patients¬†¬
Website: http://clinicaltrials.gov/ct2/show/NCT01599754?term=ADJUVANT+AXITINIB+TREATMENT+OF+RENAL+CANCER%3A+A+RANDOMIZED&rank=1¬
Principal Investigator: Jason Taksey, MD.
Research Staff:  Venita Crawford, RN: (443) 481-4393
                                 Steven P. DeMartino, CCRC, CRT, RPFT, AEC: (443) 481-4390

R0534: SPPORT: A Phase III Trial of Short term Androgen Deprivation with Pelvic Lymph Node or Prostate bed Only Radiotherapy (SPPORT) in Prostate Cancer Patients with a Rising PSA after Radical Prostatectomy
The purpose of this clinical trial is to study prostate radiation therapy. A steroid hormone called Androgen can cause the grown of prostate cancer cells. The purpose of this study is to determine how well prostate radiation therapy alone works compared to short ‚Äďterm androgen deprivation therapy given together with pelvic lymph node radiation therapy, either with or without prostate radiation therapy. This study is used in treating patients with a rising PSA after surgery for prostate cancer.
Website: link
Principal Investigator: Dr. Angel Torano ‚Äď (443)481-5800
Research Coordinator: Elizabeth Egan, R.N. ‚Äď (443)481-5811

R0815: A Phase III Prospective Randomized Trial of Dose-Escalated Radiotherapy with or without Short-Term Androgen Deprivation Therapy for Patients with Intermediate-Risk Prostate Cancer
The purpose of this study is to compare radiation therapy to androgen-deprivation therapy. Androgen-deprivation therapy may lessen the amount of androgens made by the body, which can cause the growth of prostate cancer cells. It is unknown how affective radiation therapy alone is compared with radiation therapy given together with androgen-deprivation therapy in treating patients with prostate cancer.
Website: http://clinicaltrials.gov/ct2/show/NCT00936390?term=A+Phase+III+Prospective+Randomized+Trial+of+Dose-Escalated+Radiotherapy&rank=1
Principal Investigator:
Dr. Angel Torano ‚Äď (443)481-5800
Research Coordinator: Elizabeth Egan, R.N. ‚Äď (443)481-5811

Our Studies